DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Ponesimod is an investigational drug.
There have been 8 clinical trials for Ponesimod. The most recent clinical trial was a Phase 1 trial, which was initiated on July 13th 2017.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Graft vs Host Disease. The leading clinical trial sponsors are Actelion, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].
There are twenty-eight US patents protecting this investigational drug and two hundred and sixty-three international patents.
Recent Clinical Trials for Ponesimod
|A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State||Janssen Pharmaceutica N.V., Belgium||Phase 1|
|Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis||Actelion||Phase 3|
|Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)||Actelion||Phase 3|
Top disease conditions for Ponesimod
Top clinical trial sponsors for Ponesimod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ponesimod||Get Started for $10||WT1 peptide cancer vaccine composition for transdermal administration||NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP)||Get Started for $10|
|Ponesimod||Get Started for $10||Vaccine composition||NITTO DENKO CORPORATION (Osaka, JP)||Get Started for $10|
|Ponesimod||Get Started for $10||Stabilization of alcohol intoxication-induced cardiovascular instability||UNIVERSITY OF SOUTH FLORIDA (Tampa, FL)||Get Started for $10|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ponesimod||Canada||CA2840941||2033-02-05||Get Started for $10|
|Ponesimod||China||CN103961699||2033-02-05||Get Started for $10|
|Ponesimod||European Patent Office||EP2762152||2033-02-05||Get Started for $10|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|